Replies to post #105455 on Biotech Values

[DewDiligence]

I was just basing it on the $40m profit (based on a 10% profit share) for MNTA that seems to be the consensus in the 2-way plus authorized generic case…

In the multiple-generic case, MNTA’s take is roughly 10% of sales, not 10% of profits.